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Introduction
Fluorescence-guided resections have become popular for contrast-enhancing malignant gliomas. This is based on the fact that contrast enhancement correlates with fluorescence and is generally proposed as a surrogate marker for selection of patients for fluorescence-guided resections (FGRs). However, relying only on the fluorescence may sometimes be insufficient. We would like to illustrate this by a case we recently encountered.
Case Description
A 56-year-old man presented with history of uncontrolled seizures of recent onset. He had no other focal neurologic deficits. Magnetic resonance imaging (MRI) of the brain revealed a focal peripherally enhancing right frontal lesion. It showed central necrosis with T2 hyperintense signal extending beyond the enhancement (►Fig. 1). The imaging findings were consistent with a malignant glioma. Surgery was performed with pretreatment with aminolevulinic acid (Gliolan, Medac GmbH, Wedel, Germany). Navigated craniotomy was performed using a navigable three-dimensional ultrasound (3D US) system, SONOWAND (SonoWand AS, Trondheim, Norway). After durotomy, under the microscope's BLUE 400 filter (OPMI Pentero, Carl Zeiss GmbH, Oberkochen, Germany), the tumor showed bright red fluorescence when the cortex was exposed. It appeared nodular and relatively well circumscribed and was easily removed with no residual fluorescence (►Fig. 2a). We routinely perform intraoperative 3D US for resection control in all cases. To our surprise, the postresection US revealed a sizeable residual hyperechoic tumor component (►Fig. 2b) that showed no fluorescence. This was subsequently resected completely. The patient had an uneventful recovery. Postoperative MRI showed no residual tumor. The histopathology revealed typical glioblastoma features in the fluorescing component, whereas the nonfluorescing region showed features of anaplastic astrocytoma.
FGR using aminolevulinic acid (ALA) has been demonstrated to be superior to white (microscopic) light in resecting contrast enhancing malignant gliomas. Using ALA FGR, gross total resection (GTR) rates can be almost doubled, with a beneficial effect on progression-free and overall survival (though the latter has not yet been directly demonstrated).
1,2 The fluorescence has been shown to parallel tumor contrast enhancement as depicted on MRI but can be a more sensitive technique of delineating tumor extent. 3 This has been shown indirectly by Schucht et al (by calculating the volume of nonenhancing tumor beyond contrast-enhancing boundaries that can be resected) 4 directly by Coburger et al (using a meticulous coregistration of ALA and intraoperative MRI [iMRI]). 5 However, there are still limitations to this technique of fluorescence. Visualized fluorescence is a subjective interpretation, with the surgeon usually describing it as "strong" or "bright" and "weak" or "vague." Generally strong/bright fluorescence has been associated with high positive predictive value in detecting high-grade solid tumor areas. 6 However, at the tumor margins the fluorescence typically seen is faint/weak/vague. This is not surprising as the border zone usually shows infiltrating, lower-grade tumor areas (even in a glioblastoma). This faintly visible fluorescence may be variably interpreted by different surgeons (making it relatively less reliable). Further, the predictive value of this faint fluorescence has been consistently shown to be less than desirably accurate. More objective and sensitive methods to record and interpret this fluorescence (spectrometry and confocal microscopy) may be useful, but they remain to be clinically validated. 7 Occasionally, fluorescing tumor may be hidden behind nonfluorescing brain tissue. Therefore, absence of visualized fluorescence does not necessarily exclude tumor (the "false negatives"). Hence, some other modality/strategy may be necessary to aid tumor resection. This is illustrated by our case exemplarily. There was a significant nonfluorescing (and nonenhancing) component that would have been overlooked if not for the US. Tsugu et al have shown that in nonenhancing tumors, iMRI is better than ALA. 8 Intraoperative US has long been used as an aid to localize intracranial tumors. With improved technology, navigated 3D US has been shown to be as good as iMRI in delineation of gliomas, 9 especially for the nonenhancing component. Glioblastomas, though usually contrast enhancing, can have a significant nonenhancing component. The preoperative MRI T2/FLAIR is useful to identify this component. However, it may still be difficult to differentiate from edema. As in our case, even seemingly enhancing glioblastoma multiformes (GBMs) may have a large nonenhancing part that may be overlooked unless careful attention is paid to the MRI. Only relying on the ALA fluorescence would have led to an incomplete resection in our case. We have earlier shown that ALA and US are complementary. 10 This case reinforces the same conclusion and further underlines the need for a combined modality intraoperative imaging strategy even in enhancing brain tumors. The ALA fluorescence guides the resection of the viable potentially high-grade core, whereas the navigated US is helpful in localization and resection control especially in the nonenhancing border-zone as well for the deeper "invisible" tumor component (►Fig. 3). Recent evidence supports an oncologic benefit of resecting this nonenhancing component. Of course, it goes without saying that intraoperative functional mapping and monitoring is indispensable and should be used in and around eloquent areas. Judicious combination of these tools is the key to maximize benefit of resective surgery for enhancing gliomas. The aim of our report is to reiterate the fact that mere contrast enhancement can no longer be regarded as a reliable marker of tumor extent in malignant gliomas. Consequently, there is a need to combine ALA FGR with a complementary imaging adjunct to provide maximum benefit. and C corresponds to nonenhancing, nonfluorescing tumor. Whereas ALA would be sufficient for A and B, ultrasound is essential for removing C. ALA, aminolevulinic acid.
